NCT06831786

Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers

Immunogenicity to SARS-CoV-2 of Co-administering Bivalent mRNA BNT162b2 Booster and Quadrivalent Influenza Vaccine Among Healthy Volunteers: A Pilot Study

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Prince of Songkla University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.

Conditions

• COVID - 19

Interventions

Type	Name	Description
BIOLOGICAL	Bivalent mRNA SARS-CoV-2 vaccine	Administering a booster dose of the bivalent mRNA vaccine BNT162b2
BIOLOGICAL	Quardrivalent influenza vaccine	Administering a VaxigripTetra™

Timeline

• Start date: 2024-03-01
• Primary completion: 2024-05-31
• Completion: 2024-05-31
• First posted: 2025-02-18
• Last updated: 2025-12-04
• Results posted: 2025-12-04

Locations

1 site across 1 country: Thailand